Dallas, Texas, Oct. 27, 2022 (GLOBE NEWSWIRE) -- The adoption of sedentary lifestyles that increase obesity rates and the development of chronic diseases like cancer, diabetes, and cardiovascular diseases (CVDs) are driving the global imbruvica market expansion. However, the significant costs associated with the development of biologic medications limit market expansion. Improving and updating healthcare infrastructure, as well as an increase in the burden of chronic diseases over time, are predicted to fuel market expansion.
The global imbruvica (Ibrutinib) market is anticipated to be worth USD 5.19 in 2019 billion and is expected to grow to USD 66.29 billion by 2030, at a CAGR of 26.3% during the forecast period.
Furthermore, the rising prevalence of cancer, combined with technological advancement, is likely to fuel the expansion of the imbruvica market. Other variables such as better reimbursement scenarios, increasing public awareness, and a rise in disposable income are also projected to drive market expansion. However, multiple imbruvica adverse effects and the high cost of the drug are projected to stifle the expansion of the imbruvica market. Likewise, increased R&D, clinical trials, and regulatory approvals are projected to generate sufficient opportunities in the imbuvica market over the projection period.
Global imbruvica (Ibrutinib) market scope:
| Metrics | Details |
| Study Period | 2020-2030 |
| Market Size in 2030 | US $66.29 billion |
| Segment Covered | Type, Regions |
| by Type Covered | Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenstroms Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma and Chronic Graft-Versus-Host-Disease |
| Regions Covered | North America, Europe, Asia Pacific, Middle East, and Africa and South America |
| Key Players Profiled | Beacon Pharmaceuticals, Janssen Pharmaceuticals, Johnson and Johnson, Pharmacyclics, Incepta Pharmaceuticals, and Bluepharma |
Request a pdf brochure @ https://www.adroitmarketresearch.com/contacts/request-sample/839
In yet another significant move, the European Commission has approved to increase the commercial scope of Janssen's imbruvica for particular cancer illnesses such as leukaemia. Several clinical studies and much research have preceded the invention. The key factors propelling the growth of the Imbruvica market over the forecast period are the introduction of novel cancer medicines and the increased acceptance of targeted therapy. The expansion of the competitive environment is most likely to have a positive impact on growth in the imbruvica market. Emerging countries such as India, backed by appropriate healthcare spending and indigenous active R&D initiatives, are poised to considerably impact growth prospects in the global imbruvica market.
Imbruvica aids in the elimination of aberrant B cells from favourable locations such as bone marrow, lymph nodes, and other anatomical regions that support abnormal cell multiplication. With the extensive use of imbruvica in the treatment of particular diseases such as haematological cancer types and lymphocytic leukaemia, the global market for imbruvica is expected to remain a thriving business in the coming years. Constant R&D expeditions, FDA approvals, rising cancer cases, adequate healthcare-related spending, and regional expansion projects all contribute to a consistent growth prognosis.
Purchase a single user copy @ https://www.adroitmarketresearch.com/researchreport/purchase/839
Imbruvica uptake is greater in North America, which is anticipated to hold the biggest market share during the projected period. This is due to factors such as the presence of well-established healthcare facilities, an increased prevalence of cancer, government usage approvals, and technological improvements. It is projected that the rising economies, particularly those in the Asia-Pacific region, will see expanded market size as a result of greater accessibility to healthcare facilities in the region, advantageous reimbursement scenarios, and increased awareness.
For instance, the FDA approved Imbruvica (imbruvica) in combination with obinutuzumab in January 2019 for the treatment of patients with CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma), the most common kind of adult leukaemia, who have not received prior treatment.
Important points from the Table of Contents:
1. Introduction
2. Research Methodology
3. Market Outlook
4. Competitive Landscape
5. By Type, 2019-2029 (USD Million)
6. By End Users, 2019-2029 (USD Million)
7. By Application, 2019-2029 (USD Million)
8. Regional Overview, 2019-2029 (USD Million)
North America
• US
• Canada
Europe
• Germany
• France
• UK
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Rest of Asia Pacific
South America
• Mexico
• Brazil
• Rest of South America
Middle East and South Africa
9. Company Profiles
10. Appendix
Looking for DISCOUNT? If yes, then request for discount at https://www.adroitmarketresearch.com/contacts/discount/839
Access research repository of Upcoming Reports @ https://adroitmarketresearch.com/upcoming.html
About Us:
Adroit Market Research is a global business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a market’s size, key trends, participants and future outlook of an industry. We intend to become our clients’ knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code– Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.
Contact Us:
Ryan Johnson
Account Manager - Global
3131 McKinney Ave Ste 600
Dallas, TX 75204
Email ID: sales@adroitmarketresearch.com
Phone No.: +1-9726644514, +91-9665341414
Connect with us: Facebook | Twitter | LinkedIn
